Farmaindustria’s protection of personal data in research is already a benchmark in Europe and is a further incentive to attract clinical trials to Spain.

The Code of Conduct regulating the processing of personal data in clinical trials approved in 2022 makes it easier for companies and researchers to correctly comply with their obligations in the protection of data for scientific research purposes. That of the pharmaceutical industry was the first sectoral code approved by the Spanish Data Protection Agency […]

Medicines for rare diseases already account for 39% of those authorised in Europe, but take more than two years to reach Spain

The director of Farmaindustria’s Access Department, Isabel Pineros, participates in the XVI International Congress on Rare Diseases: “In recent years we have seen great advances in orphan drug research, but much remains to be done to ensure that this benefit reaches all patients who need it when they need it”. Farmaindustria has presented a document […]

New drugs reduce cancer deaths in Spain by almost 30%.

This is demonstrated by a recent study by Professor Frank R. Lichtenberg of Columbia University, which has just been published in the journal Value in Health. Lichtenberg analysed the relationship between pharmaceutical innovation and cancer mortality in Spain between 1999 and 2016. The use of new cancer drugs in this period increased patients’ life expectancy […]

Precision medicine opens new hopes in breast cancer: 14 targeted therapies authorized since 2018

On World Disease Day, which is celebrated on October 19, Farmaindustria remembers the importance of clinical trials, the previous step for the arrival of innovative treatments One in eight women will develop breast cancer in her lifetime, according to current estimates. Figures that, in Spain, represent around 35,000 new cases in 2023, according to the […]

Farmaindustria launches a proposal to speed up the delivery of innovative medicines to patients in cases where the benefit is most relevant

The document proposes, without the need for a regulatory change, a procedure that would allow the equitable arrival of drugs that meet certain criteria that make their funding more urgent. “We need to ensure that all patients receive the best possible treatment on an equitable basis, and sometimes this is not possible through the usual […]

Urgent measures are needed to encourage innovation and production and enable Europe to make up lost ground.

elglobal.es   In a political context with elections called for the European Parliament at the beginning of June 2024 and with Spain holding the presidency of the European Council from July until December of this year, the new European pharmaceutical legislation has not yet taken its final shape. Icíar Sanz de Madrid, Director of International […]

Paediatric clinical research advances in Spain driven by collaboration between researchers, healthcare professionals and the pharmaceutical industry

Between 2020 and 2022, 446 clinical trials with children and adolescents were conducted in our country, almost half of them focused on rare diseases and 90.4% promoted by the industry. Nearly 40 pharmaceutical companies and more than 30 researchers attended the 6th Monographic Conference on clinical research in paediatrics, organised by the Spanish Network of […]

“Artificial intelligence and technology are driving digital therapies, which benefit not only patients, but the healthcare system and society as a whole”.

In recent years, the number of applications capable of interacting with patients to prevent, manage or treat diseases has increased, and which can also generate data that can be incorporated into medical records and provide evidence in real life. The director of Farmaindustria’s Research Department, Pedro Luis Sánchez, participates in the conference Personalised digital care […]

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research

The 7th Congress of Patients’ Organisations, organised by the POP, analyses the application of the new European Regulation on Clinical Trials. Farmaindustria’s director general, Juan Yermo, stresses that this regulation is more demanding in terms of procedure and deadlines, and that this requires centres with sufficient resources and infrastructure to prevent researchers from wasting time […]

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society

The vast majority of them are aimed at modifying the course of the disease, according to an Iqvia report on the future of R&D. In Spain alone there are already more than 800,000 people suffering from the most common form of dementia. Tomorrow, 21 September, is World Alzheimer’s Day, which the Spanish patients’ confederation Ceafa […]